HFAI

Heart Failure Association of India

[Open Heart @Open_HeartBMJ]

Mineralocorticoid receptor antagonists in heart failure with sustained monomorphic ventricular tachycardia: comparative analysis of spironolactone versus eplerenone.@drkarthik2010 @BoopathyCardio @SanjitSJolly @hfaimedia
https://t.co/lt6JSBiIdJ

[Prabhakar Dorairaj @prabhud19]

Potassium levels and mortality in HF. - sweet spot is 4.2 to 5. Up to 5.5 is not associated with worse outcomes

[Prabhakar Dorairaj @prabhud19]

Lpa and CAC >300 the deadly duo

[JAMA @JAMA_current]

📊 JAMA Clinical Guidelines Synopsis: The 2025 guideline for #ACS management recommends dual antiplatelet therapy with aspirin and a P2Y12 inhibitor, high-intensity statins, invasive revascularization, and radial access for angiography.

https://t.co/DeGwgylVMh

[JAMA @JAMA_current]

📊 JAMA Clinical Guidelines Synopsis: The 2024 guideline from the American Heart Association and American College of Cardiology recommends continuing statins and β-blockers for patients undergoing noncardiac surgery.

https://t.co/UKVSirJSnx

[Ahmed Bennis MD 🫀 @drbennisahmed]

🫘 Adding nsMRA to RASi+SGLT2i could delay kidney failure by ~12 years:
🔴 RASi+SGLT2i alone → eGFR hits 10 mL/min at ~16 years
🟢 Triple therapy (+nsMRA) → eGFR hits 10 mL/min at ~28 years
Same starting eGFR of 66. One extra pill. ≈12 years of kidney function preserved.

[Ahmed Bennis MD 🫀 @drbennisahmed]

SGLT2 Inhibitors: The Evidence is Overwhelming

Meta-analysis across T2DM, Heart Failure & CKD — consistent 23-24% reduction in CV death/HHF

Benefits consistent across ALL populations — including patients with all 3 comorbidities simultaneously

#SGLT2 #HeartFailure #CKD

[Amelia Carro — Instituto Corvilud @icorvilud]

INCLISIRAN
✍️Fast-track lipid-lowering treatment early after an acute coronary syndrome
🌏Real-World-Data on ACS patients
⬇️LDL: 147->30 mg/dl
👍🏻50% achieved goals at 15d
👍🏻100% achieved goals at 30 d
https://t.co/vZg76U1abD

[Ahmed Bennis MD 🫀 @drbennisahmed]

🚨 GLP-1 RA in HFrEF — the data is striking.
n=1,275 vs 1,275 · PSM 1:1 · 1-year follow-up
All-cause mortality: 7.1% vs 10.2% → OR 0.68 (p=0.006)

ADHF hospitalization: 27.7% vs 32.8% → OR 0.79 (p=0.005)

GLP-1 RAs were previously cautioned against in severe HFrEF.

[HFAI @hfaimedia]

Good algorithm for HF based on eGFR

[Ahmed Bennis MD 🫀 @drbennisahmed]

🫀 Managing Heart Failure in CKD — a practical framework by eGFR:

HFpEF:

•eGFR 15-29 → SGLT2i (if >20), nsMRA (if >25)

•eGFR 30-59 → SGLT2i + nsMRA + ARNI if EF closer to 50%

•eGFR ≥60 → same + nsMRA

[HFAI @hfaimedia]

BMI was 26.8+

[HFAI @hfaimedia]

In this post hoc secondary analysis of the SOUL randomized clinical trial, oral semaglutide was associated with early and sustained improvements vs placebo in multiple ASCVD risk factors in high-risk participants with T2D and ASCVD and/or CKD, incremental to SoC.

[JAMA Cardiology @JAMACardio]

#Type2Diabetes patients at high cardiovascular risk receiving oral #semaglutide demonstrated early and sustained improvements in glycated hemoglobin, body weight, systolic blood pressure, and lipid profiles vs placebo. https://t.co/ZZcCk9KIgL

[Ahmed Bennis MD 🫀 @drbennisahmed]

Efficacy and Safety of Simultaneous Initiation of SGLT2 Inhibitors and Mineralocorticoid Receptor Antagonists in Patients With CKD or HF

simultaneous initiation of an SGLT2 inhibitor and an MRA produced greater reductions in albuminuria

https://t.co/i6sVTuAqgr

[CardiovascularCorner @TrackYourHeart]

Acute MI is not always STEMI.

A major 2025 review highlights why relying only on classic STEMI criteria can miss dangerous coronary occlusions.

A thread on OMI (Occlusion Myocardial Infarction): 🧵

[HFAI @hfaimedia]

@JAMACardio LBBB is better why do you tweet inferior.... 🤔

[JAMA Cardiology @JAMACardio]

In patients with #HeartFailure and #LBBB, conduction system pacing (#CSP) was inferior to biventricular pacing (#BiVP) for a composite of death, heart failure events, and LVEF change at 12 months.

https://t.co/Epqiuvo70e

[HFAI @hfaimedia]

Finerenone for non-diabetic CKD

[Ahmed Bennis MD 🫀 @drbennisahmed]

🚨 FIND-CKD — Positive Results!
Finerenone (Kerendia) has met its primary endpoint in the Phase III FIND-CKD trial in patients with non-diabetic CKD. 🎯
📊 Topline results (March 16, 2026):
▸ Statistically significant improvement vs placebo in eGFR slope over 32 months

[HFAI @hfaimedia]

MACE reduction and renal outcomes are showing best results with GLP1RA

[Ahmed Bennis MD 🫀 @drbennisahmed]

New meta-analysis of 83,004 patients across 20 RCTs confirms GLP-1 receptor agonists significantly reduce:
🫀 MACE (RR 0.87)
💀 All-cause death (RR 0.89)
❤️ CV death (RR 0.88)
🧠 Stroke (RR 0.88)
🫘 Composite renal outcomes (RR 0.80)

[Ahmed Bennis MD 🫀 @drbennisahmed]

Unexplained dyspnea? Here’s the new ESC framework for diagnosing HFpEF — and it goes way beyond a basic echo 🧵
From Landsteiner et al., Eur Heart J 2026, a stepwise domain-based approach